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Key Points
• 5-FU is the first-line chemotherapy for colorectal cancer; its use is associated with severe long-term
gastrointestinal side-effects. Mechanisms underlying 5-FU-induced gastrointestinal dysfunction have not been
investigated in depth.
• This is the first study in a mouse model demonstrating that short-term 5-FU treatment induces increased
gastrointestinal transit associated with acute intestinal inflammation, which may lead to persistent changes in
the ENS contributing to delayed gastrointestinal transit and colonic dysmotility.
• These findings provide insight into the mechanisms underlying chemotherapy-induced gastrointestinal
dysfunction.
Abstract
Background The use of the anticancer chemothera-
peutic agent 5-fluorouracil (5-FU) is often limited by
nausea, vomiting, constipation, and diarrhea; these
side-effects persist long after treatment. The effects of
5-FU on enteric neurons have not been studied and
may provide insight into the mechanisms underlying
5-FU-induced gastrointestinal dysfunction. Methods
Balb/c mice received intraperitoneal injections of 5-
FU (23 mg/kg) 3 times/week for 14 days. Gastroin-
testinal transit was analysed in vivo prior to and
following 3, 7, and 14 days of 5-FU treatment via
serial x-ray imaging. Following 14 days of 5-FU
administration, colons were collected for assessment
of ex vivo colonic motility, gross morphological struc-
ture, and immunohistochemical analysis of myenteric
neurons. Fecal lipocalin-2 and CD45+ leukocytes in
the colon were analysed as markers of intestinal
inflammation. Key Results Short-term administration
of 5-FU (3 days) increased gastrointestinal transit,
induced acute intestinal inflammation and reduced
the proportion of neuronal nitric oxide synthase-
immunoreactive neurons. Long-term treatment (7,
14 days) resulted in delayed gastrointestinal transit,
inhibition of colonic migrating motor complexes,
increased short and fragmented contractions, myen-
teric neuronal loss and a reduction in the number of
ChAT-immunoreactive neurons after the inflamma-
tion was resolved. Gross morphological damage to the
colon was observed following both short- and long-
term 5-FU treatment. Conclusions & Inferences Our
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results indicate that 5-FU induces accelerated gas-
trointestinal transit associated with acute intestinal
inflammation at day 3 after the start of treatment,
which may have led to persistent changes in the ENS
observed after days 7 and 14 of treatment contributing
to delayed gastrointestinal transit and colonic
dysmotility.
Keywords 5-fluorouracil, 5-FU, colonic motility, en-
teric neuropathy, gastrointestinal transit, myenteric
neurons.
Abbreviations: 5-FU, 5-fluorouracil; CMMC, colonic
migrating motor complex; CRC, colorectal cancer;
ENS, enteric nervous system; FC, fragmented contrac-
tion; IR, immunoreactive; SC, short contraction.
INTRODUCTION
Colorectal cancer (CRC) is a leading cause of cancer
related mortality,1–3 leading to over 1 million deaths
annually4; it is one of the most frequently diagnosed
cancers worldwide. Due to late stage diagnosis approx-
imately 50% of patients have metastasis to surround-
ing tissues, most frequently to the liver.5 Therefore,
dual therapy consisting of chemotherapy and surgical
resection is common.6
Since the discovery of fluoropyrimidines in the
1950’s, 5-fluorouracil (5-FU) has been the backbone of
therapy for many solid tumors and is considered as the
standard first line therapy for metastatic CRC.7
5-fluorouracil is an analogue of uracil with a fluorine
atom at the C-5 position in place of hydrogen.8 Upon
entering a cell, 5-FU is converted intracellularly to
several active metabolites: fluorodeoxyuridine
monophosphate, fluorodeoxyuridine triphosphate, and
fluorouridine triphosphate. These active metabolites
exert their cytotoxic effects via misincorporation of
fluoronucleotides into RNA and inhibition of nucleo-
tide synthetic enzyme thymidylate synthase.9
Combination therapies including 5-FU are reported
to improve response rates for advanced CRC by 40–
50%,10,11 however, severe gastrointestinal side-effects
such as nausea, vomiting, constipation, and diarrhea
remain significant hurdles in the clinical application of
5-FU. It has been suggested that 5-FU-induced gas-
trointestinal dysfunction results from inflammation,
epithelial degradation, and intestinal ulceration trig-
gering intestinal mucositis.12 However, recent evi-
dence suggests that 5-FU induced gastrointestinal
dysmotility outlasts intestinal mucositis.13 One sys-
tem that has been overlooked in 5-FU-induced gas-
trointestinal dysfunction is the enteric nervous system
(ENS), embedded within the wall of the gastrointesti-
nal tract and controlling its functions.14 Neuronal loss
and phenotypic changes within the ENS following
chemotherapeutic administration of other agents, cis-
platin and oxaliplatin, have been found to result in
downstream effects on gastrointestinal muscle tone
and transit.15,16
The aims of this study were to investigate the effects
of short- and long-term 5-FU treatment on: (i) gastroin-
testinal transit time and gastric emptying; (ii) ex vivo
colonic motility functions; (iii) histological architec-
ture of the colonic mucosa; (iv) level of inflammation
in the colon; and (v) the total number of myenteric
neurons and subpopulations of inhibitory and excita-
tory neurons controlling colonic motility.
MATERIALS AND METHODS
All procedures were approved by the Victoria University Animal
Experimentation Ethics Committee and performed in accordance
with the guidelines of the National Health and Medical Research
Council Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes.
Animals
Male Balb/c mice aged 6–8 weeks (18–25 g) supplied from the
Animal Resources Centre (Perth, Australia) were used for the
experiments. Mice had free access to food and water and were kept
under a 12 h light/dark cycle in a well-ventilated room at an
approximate temperature of 22 °C. Mice acclimatized for up to
7 days prior to the commencement of in vivo intraperitoneal
injections. A total of 42 mice were used for this study.
In vivo 5-FU injections
Mice received intraperitoneal injections of 5-FU (23 mg/kg; Sigma-
Aldrich, CastleHill,NSW,Australia), 3 times aweek via a 26 gauge
needle. 5-FU was dissolved in 100% dimethyl sulfoxide (DMSO;
Sigma-Aldrich) to make 1 M/L stock solution refrigerated at
20 °C. The stock was then defrosted and diluted with sterile
water to make 0.1 M/L (10% DMSO) solutions for intraperitoneal
injections. The dose of 5-FU was calculated to be equivalent to
standard human dose per body surface area.17 The lowdoses of 5-FU
(10–40 mg/kg) have been shown to have antitumor efficacy in
mousemodels of cancer.18 Sham-treatedmice received 10%DMSO
in sterile water via intraperitoneal injection three times a week via
a 26 gauge needle. The injected volumeswere calculated to the body
weight; the maximum volume did not exceed 200 lL per injection.
Mice were euthanized via cervical dislocation at 3 (2 treatments), 7
(3 treatments), and 14 (6 treatments) days after the first injection
and colon was collected for in vitro experiments.
Gastrointestinal transit
Prior to performing x-ray imaging, animals were trained/condi-
tioned for oral gavage using a non-irritating substance such as 0.9%
w/v saline (volume 0.1–0.4 mL); this was repeated at least three
times with each animal with at least 24 h between each training.
© 2016 The Authors.
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The training/conditioning with restraint were done by placing the
restrainer into the mouse cages at least 24 h prior to the x-ray
procedure. Gastrointestinal transit was studied by x-ray prior to
first treatment (day 0) and following 3, 7, and 14 days of 5-FU
treatment. The contrast agent, 0.4 mL of suspended barium sulfate
(X-OPAQUE-HD, 2.5 g/mL), was administered via oral gavage.
Radiographs of the gastrointestinal tract were performed using a
HiRay Plus Porta610HF x-ray apparatus (JOC Corp, Kanagawa,
Japan; 50 kV, 0.3 mAs, exposure time 60 ms). Mice were immobi-
lized in the prone position by placing them inside a transparent
plastic restraint tube with partly open front side for breathing
which comfortably restrains animal movement essential for max-
imum of 1–2 min for successful x-ray imaging. X-rays were
captured using Fujifilm cassettes (24 9 30 cm) immediately after
administration of barium sulfate (T0) every 5 min for the first hour,
every 10 min for the second hour, then every 20 min through to
480 min (T480). Animals were closely monitored during and after
all procedures. Images were developed via a Fujifilm FCR Capsula
XLII and analysed using eFilm 4.0.2 software. Speed of gastroin-
testinal transit was calculated as time in minutes taken to reach
each region of the gastrointestinal tract (stomach, small intestines,
cecum, and large intestines). Organ emptying was calculated as the
time taken for complete barium emptying from specific gastroin-
testinal regions (stomach, small intestines).19–21
Colonic motility experiments
The entire colon was removed from day 14 sham and 5-FU-treated
mice and set up in organ-bath chambers to record motor patterns
in vitro.15 Briefly, the colon was placed into warmed (35 °C),
oxygenated physiological saline until the fecal pellets were
expelled. The empty colon was cannulated at both ends and
arranged horizontally in an organ-bath chamber. The proximal
end of the colon was connected to a reservoir containing
oxygenated physiological saline to maintain intraluminal pres-
sure. The distal end was attached to an outflow tube that provided
a maximum of 2 cm H2O back-pressure. Organ baths were
continuously superfused with oxygenated physiological saline
solution and preparations were left to equilibrate for 30 min.
Contractile activity of each segment was recorded with a Logitech
Quickcam Pro camera positioned 7–8 cm above the preparation.
Videos (2 9 20 min) of each test condition were captured and
saved in avi format using VirtualDub software (Avery Lee,
Cambridge, MA, USA) (version 1.9.11).
Colonic migrating motor complexes (CMMCs) were defined as
propagating contractions directed from the proximal to the distal
end of the colon which travelled more than 50% of the colon
length.22–24 Contractions that propagated less than 50% colon
length were considered to be short contractions (SCs). Incomplete
non-propagating phasic contractions occurring concurrently at
different parts of the colon rather than propagating over the length
of the colon were defined as fragmented contractions (FCs).
Recordings were used to construct spatiotemporal maps using in-
house edge detection software.25 Spatiotemporal maps plot the
diameter of the colon at all points during the recording allowing
contractile motor patterns to be analysed with Matlab software
(Mathworks, Natick, MA, USA) (version 12).
Drugs used
Hexamethonium Bromide (HEX; Sigma-Aldrich) and tetrodotoxin
(TTX) (Abcam, Cambridge, MA, USA) were prepared as stock
solutions and diluted in physiological saline daily before addition
to preparations.
Histology
The colon was harvested and placed in a 10% formalin solution
overnight and then transferred into 70% ethanol the following
day. Paraffin embedded colon sections were cut 5 lm thick and
de-waxed in a 60 °C oven for 30 min. To examine the morpho-
logical changes to the colon, a standard Hematoxylin and Eosin
staining protocol was followed.26,27
Immunohistochemistry in wholemount
preparations
Colon sections (2–3 cm) were placed in oxygenated phosphate-
buffered saline (PBS; pH 7.2) containing nicardipine (3 lM; Sigma-
Aldrich) for 20 min to inhibit smooth muscle contractions.
Samples were cut open along the mesenteric border, cleared of
their contents, maximally stretched and dissected mucosa up to
expose the myenteric plexus attached to the longitudinal muscle
layer. Tissues were fixed with Zamboni’s fixative (2% formalde-
hyde, 0.2% picric acid) overnight at 4 °C. Preparations were
cleared of fixative by washing 3 9 10 min with DMSO followed
by 3 9 10 min washes with PBS. Fixed tissues were stored at 4 °C
in PBS for a maximum of 5 days.
Wholemount preparations were incubated with 10% normal
donkey serum (Chemicon, EMD Millipore Corporation, Billerica,
MA, USA) for 1 h at room temperature. Tissues were then washed
(2 9 5 min) with PBS and incubated with primary antibodies
against Protein Gene Product 9.5 (PGP9.5) (chicken, 1 : 500;
Abcam), neuronal nitric oxide synthase (nNOS; goat, 1 : 500;
Abcam), and choline acetyl transferase (ChAT; goat, 1 : 200;
Abcam) overnight at 4 °C. Tissues were then washed in PBS
(3 9 10 min) before incubation with species-specific secondary
antibodies labeled with different fluorophores: donkey anti-
chicken Alexa 594 (1 : 200; Jackson Immuno Research Laborato-
ries, West Grove, PA, USA) and donkey anti-goat Alexa 488
(1 : 200; Jackson Immuno Research Laboratories) for 2 h at room
temperature. Wholemount preparations were given 3 9 10 min
final washes in PBS and then mounted on glass slides using
fluorescent mounting medium (DAKO, Glostrup Municipality,
Hovedstaden, Denmark). Wholemount preparations were
observed under a Nikon Eclipse Ti laser scanning microscope
(Nikon, Tokyo, Japan), eight randomly chosen images from each
preparation were captured with a 209 objective and processed
using NIS Elements software (Nikon). The number of PGP9.5,
nNOS, and ChAT immunoreactive neurons was quantified in the
myenteric ganglia within a 2 mm2 area of each preparation.
Immunohistochemistry in cross-sections
Colon sections (1–2 cm) were placed in oxygenated PBS containing
nicardipine (3 lM; Sigma-Aldrich) for 20 min to inhibit smooth
muscle contractions. Samples were cut open along the mesenteric
border, cleared of their contents, and pinned mucosa up without
stretching. Tissueswere fixedwithZamboni’s fixative overnight at
4 °C. Preparations were cleared of fixative by washing 3 9 10 min
with DMSO (Sigma-Aldrich) followed by 3 9 10 min washes with
PBS. After washing, tissues were embedded in 100% OCT and
frozen using liquid nitrogen (LN2) and isopentane (2-methyl
butane) and stored in 80 °C freezer. Tissues were cut at 20 lm
section thickness using Leica CM1950 cryostat (Leica Biosystems,
Wetzlar, Hesse, Germany), adhered to slides and allowed to rest for
30 min at room temperature before processing.
Cross-section preparations were incubated with 10% normal
donkey serum (Chemicon) for 1 h at room temperature. Tissues
© 2016 The Authors.
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were then washed (2 9 5 min) with PBS and incubated with
primary antibodies against CD45 (Rat, 1 : 500; BioLegend, San
Diego, CA, USA), overnight at 4 °C. Sections were then washed in
PBS (3 9 10 min) before incubation with secondary antibodies
labeledwithfluorophoredonkeyanti-ratAlexa488 (1 : 200; Jackson
Immuno Research Laboratories) for 2 h at room temperature. The
sections were given 3 9 10 min final washes in PBS and then cover
slipped using fluorescence mounting medium (DAKO). Sections
were viewed under a Nikon Eclipse Ti laser scanning microscope
(Nikon), eight randomly chosen images from each preparationwere
captured with a 209 objective and processed using NIS Elements
software (Nikon). The number of CD45+ immunoreactive cells was
quantified within a 2 mm2 area in every colonic section.
Imaging
Three dimensional (z-series) images of wholemount preparations
were taken using a Nikon Eclipse Ti laser scanning microscope
(Nikon). Fluorophores were visualized using excitation filters for
Alexa 594 Red (excitation wavelength 559 nm), Alexa 488 (exci-
tation wavelength 473 nm), and Alexa 405 (excitation wavelength
405 nm). Z-series images were taken at step size of 1.75 lm
(1600 9 1200 pixels).
Quantification of fecal lipocalin-2
Fresh fecal pellets were collected from mice after 3, 7, and 14 days
of 5-FU administration and stored immediately at 80 °C. Fecal
samples were thawed and suspended in PBS with 0.1% Tween
(100 mg/mL) overnight prior to processing. The next day samples
were centrifuged at 13.8 g at 4 °C for 10 min. Samples were then
agitated and centrifuged for another 5 min at 12 000 rpm at 4 °C.
Supernatant was collected and lipocalin-2 levels were quantified
using DuoSET ELISA Mouse Lipocalin-2 kit (R&D Systems,
Minneapolis, MN, USA).
Statistical analysis
Data were assessed using two-way ANOVA, Welch’s two-tailed
t-test, and Student’s two-tailed t-test. Analyses were performed
using Graph Pad Prism (Graph Pad Software Inc., San Diego, CA,
USA). Data are presented as mean  SEM. Value differences were
considered statistically significant at p < 0.05.
RESULTS
Altered gastrointestinal transit following 5-FU
administration
To determine the effects of 5-FU administration on
gastrointestinal transit, series of radiographic images
were used to track barium sulfate throughout the
gastrointestinal tract before the first injection (day 0),
after two injections (day 3), three injections (day 7), and
six injections (day 14; Figs 1 and 2, Table 1). The speed
of barium movement was calculated by tracing barium
entry from one part of the gastrointestinal tract to the
next. After 3 days of 5-FU administration, movement
of barium in both the cecum and colon was faster than
before treatment (Fig. 2A), however, after 7 and
14 days of 5-FU administration barium movement
was significantly delayed compared to day 0 in the
cecum and colon (Fig. 2A, Table 1).
Although tracing barium movement allowed analy-
sis of real time transit speed, gastrointestinal organ
filling and emptying does not happen simultaneously,
thus we further analysed the time taken for complete
barium emptying from specific regions.
No changes in gastric emptying time were observed
at day 3 of 5-FU administration, but significant delays
in gastric emptying were seen after 7 and 14 days of 5-
FU administration (Fig. 2B, Table 1). Intestinal empty-
ing was faster after 3 days of 5-FU administration, but
significantly delayed after both 7 and 14 days of 5-FU
administration (Fig. 2C, Table 1).
Pellet formation time was decreased after 3 days of 5-
FU administration (Fig. 2D), but significantly increased
after 7 and 14 days of 5-FU administration (Fig. 2D).
Thus, increased intestinal transit was observed after
short-term 5-FU treatment, while prolonged treatment
induced delays in gastrointestinal transit.
Changes in colonic motility following 5-FU
treatment
To investigate effects of 5-FU treatment on colonic
motility, excised colons were studied in organ bath
experiments at day 14 of 5-FU treatment. The total
number of contractions (including all types of motor
patterns in the colon: CMMCs, short and FCs,
Fig. 3A) was increased in colons from 5-FU-treated
animals compared to sham-treated mice (sham:
27.7  1.4, 5-FU: 36.1  2.1, p < 0.01, Fig. 3B). To
determine if this increase was due to changes in a
specific type of motor activity, the frequency, propor-
tion, and propagation speed were analysed for each type
of motor pattern.
Colonic migrating motor complexes were defined as
sustained anally directed contractions propagating
more than 50% of the colon length. Colonic migrating
motor complexes are mediated mainly by myenteric
neurons, although inputs from the mucosa may mod-
ulate their activity.28 In vivo treatment with 5-FU was
associated with a decrease in the frequency of CMMCs
in comparison with sham-treated mice (sham:
11.2  0.6, 5-FU: 3.5  1.0, p < 0.0001, Fig. 3B). Sim-
ilarly, the proportion of CMMCs following 5-FU
treatment was significantly decreased compared to
sham-treated mice (sham: 41.1  3.0%, 5-FU:
12.4  3.8%, p < 0.0001, Fig. 3C). No significant dif-
ference in the speed of CMMCs was found between
sham-treated and 5-FU-treated mice (sham:
2.9  0.2 mm/s, 5-FU: 2.3  0.3 mm/s, Fig. 3D).
© 2016 The Authors.
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Contractions that propagated less than 50% of the
colon lengthwere termed SCs (Fig. 3A). Treatmentwith
5-FU resulted in both increased frequency (sham:
10.1  1.1, 5-FU: 20.5  3.0, p < 0.01, Fig. 3B) and
increased proportion (sham: 36.0  2.2%, 5-FU:
54.2  4.1%, p < 0.01, Fig. 3C) of SCs in the colon. A
significant increase in the speed of SCs was found
following 5-FUadministrationwhencompared to sham-
treated mice (sham: 0.7  0.0 mm/s, 5-FU:
1.9  0.3 mm/s,p < 0.01, Fig. 3D). Incomplete contrac-
tions that did not propagate, but rather occurred con-
currently over the length of the colon were defined as
FCs. Both the frequency (sham: 6.4  0.8, 5-FU:
11.8  1.2, p < 0.01, Fig. 3B) and the proportion (sham:
22.9  2.3%, 5-FU: 32.5  1.8%, p < 0.01, Fig. 3C) of
FCs were significantly higher in 5-FU-treated compared
to sham-treated mice. No significant difference in the
speed of FCswas found between sham-treated and 5-FU-
treated mice (sham: 1.5  0.1 mm/s, 5-FU:
2.1  0.3 mm/s, Fig. 3D).
To investigate whether neurogenic components are
involved in the recorded colonic motor patterns, a
voltage-gated sodium channel blocker TTX and a nico-
tinic cholinergic antagonist HEX were added into the
organ baths. TTX (1 lM, 20 min) abolished CMMCs,
SCs, and FCs in colons fromboth shamand 5-FU-treated
mice (Fig. 3E), indicating that these motility patterns
are neurogenic. However, a persistent TTX-resistant
Figure 1 X-ray images following repeated
in vivo 5-FU (23 mg/kg, 3 times/week)
administration. Representative x-ray images
obtained from mice 0–210 min after
intragastric barium sulfate (0.4 mL, 2.5 mg/
mL) administration at day 0 (prior to 1st
injection) and following 3, 7, and 14 days of
5-FU administration.
© 2016 The Authors.
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tonic constriction in the distal part of the colon blocked
byHEX (100 lM, 20 min) was observed in sham-treated
mice. In 5-FU-treated mice, TTX-resistant tonic con-
strictions were prominent in both proximal and distal
parts of the colon; the proximal tonic constriction was
not blocked by application of HEX (Fig. 3E).
Morphological damage to the colon following
5-FU administration
Colonic architecture from sham-treated animals at
days 3, 7, and 14 appeared healthy with a visible brush
border and uniform crypts (Fig. 4A–C). Histological
examination of the colon at day 3 from the 5-FU-
treated group demonstrated no obvious changes to the
epithelial brush border; however, there was a severe
loss of colonic crypts and goblet cells and cellular
infiltration within the lamina propria when compared
to the sham-treated group (Fig. 4A and A’). By days 7
and 14, there was thickening of the epithelial brush
border indicative of regeneration of the colonic crypts
in the 5-FU-treated groups, but they still appeared
short, distended, and disorganized with an increased
number of goblet cells (Fig. 4B’ and C’) when compared
to colon from the sham-treated group (Fig. 4B and C).
Intestinal inflammation following 5-FU
treatment
To investigate if 5-FU treatment causes inflammation,
immune cell infiltration in the colon and the concen-
tration of a neutrophil gelatinase-associated protein,
Figure 2 Gastrointestinal transit time, gastric and intestinal emptying following repeated in vivo 5-FU administration. (A) Time (min) taken for
barium sulfate to reach the stomach, small intestines, cecum, and large intestines before (day 0) and at 3, 7, and 14 days following 5-FU
administration. (B) Time (min) taken for complete emptying of barium from the stomach. (C) Time (min) taken for complete emptying of barium from
the small intestines. (D) Time (min) taken to form first pellet before (day 0) and at 3, 7, and 14 days following 5-FU administration. Data represented
as mean  SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 6 per group/time point.
© 2016 The Authors.
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lipocalin-2, a highly sensitive biomarker for intestinal
inflammation29,30 in fecal samples were analysed.
Immune cells in colonic-cross sections were labeled
with a pan leukocyte marker anti-CD45 antibody
following 3 (Fig. 5A and A’), 7 (Fig. 5B and B’), and 14
(Fig. 5C and C’) days of sham and 5-FU treatment.
Total numbers of CD45 positive cells were counted
within a 2 mm2 area. A significant increase in the
number of CD45 positive cells was found in the colon
following 3 days of 5-FU administration (99  2,
p < 0.0001) when compared to sham (48  1, Fig. 5D).
No significant changes in the number of CD45 positive
leukocytes were found after 7 (sham: 49  2, 5-FU:
53  3) and 14 (sham: 51  4, 5-FU: 54  0.1) days of
treatment (Fig. 5D). A significant increase in the
concentration of lipocalin-2 was observed at day 3
after 5-FU administration (1592  160 ng, p < 0.05)
compared to sham-treated mice (883  100 ng), but
not at days 7 (sham: 946  230 ng, 5-FU:
867  210 ng) and 14 (sham: 1122  160 ng, 5-FU:
881  120 ng) (Fig. 5E).
Reduction in the total number of myenteric
neurons and changes in neuronal subpopulations
following administration of 5-FU
To investigate any changes to the total number of
myenteric neurons, wholemount preparations of the
colon were labeled with anti-PGP9.5 antibody to count
neurons within a 2 mm2 area. Repeated in vivo admin-
istration of 5-FU induced myenteric neuronal loss at
days 7 (sham: 1225  6; 5-FU: 1150  5, p < 0.001) and
14 (sham: 1229  3; 5-FU: 1091  5, p < 0.001), but
not at day 3 (sham: 1234  4; 5-FU: 1231  10, Fig. 6).
To determine if 5-FU administration was associated
with changes in subpopulations of myenteric neurons
controlling intestinal muscle activity, inhibitory mus-
cle motor, and interneurons IR for nNOS (Fig. 7) and
neurons IR for ChAT (Fig. 8) were analysed.
Fewer nNOS-IR neurons were observed at days 3
(sham: 357  7; 5-FU: 286  3, p < 0.0001) and 14
(sham: 380  11; 5-FU: 310  3, p < 0.0001) following
5-FU administration (Fig. 7A’ and C) when compared to
sham (Fig. 7A and C). However, no reduction in the
number of nNOS-IR neurons from the 5-FU-treated
group was observed at day 7 (sham: 363  5; 5-FU:
341  4; Fig. 7B, B’ and D). The proportion of nNOS-IR
neurons was reduced on day 3 (sham: 29.5  0.3%; 5-
FU: 23.8  0.3%) when compared to sham (p < 0.01,
Fig. 7E), but not on days 7 (sham: 29.3  0.6; 5-FU:
29.7  0.3) and 14 (sham: 30.9  0.9; 5-FU: 28.5  0.4,
Fig. 7E).
The total number of ChAT-IR neurons increased on
day 3 (sham: 294  4; 5-FU: 319  4), but decreased on
days 7 (sham: 322  2; 5-FU: 300  4) and 14 (sham:
320  3; 5-FU: 282  5) following 5-FU administration
(Fig. 8A’, B’, C’, and D) when compared to the sham-
treated group (Fig. 8A–D). However, no significant
difference in the proportion of ChAT-IR neurons was
observed at any time point after 5-FU administration
began (Fig. 8E).
DISCUSSION
This study is the first to examine 5-FU-induced enteric
neuropathy and its effect on gastrointestinal function.
Our results show that 5-FU administration causes a
significant increase in gastrointestinal transit time at
day 3, but delays in intestinal and gastric emptying at
days 7 and 14. Significant reductions in the frequency
and proportion of CMMCs, but increased frequency
and proportions of short and FCs were prominent after
14 days of 5-FU treatment. All types of contractions
were abolished by TTX; a residual tonic constriction in
the distal colon was blocked by HEX in both sham and
5-FU-treated mice. A TTX-resistant tonic constriction
of the proximal colon seen in 5-FU–treated mice was
not blocked by HEX. Severe crypt ablation and mucosal
destruction occurred in the colon at day 3. Consistent
crypt disorganization and hypoplasia persisted
throughout the experimental period; however, mucosal
barrier regeneration was evident after both 7 and
14 days. Acute inflammation, confirmed by increased
levels of fecal lipocalin-2 and CD45 positive leuko-
cytes in the colon, was seen on day 3 of 5-FU treatment
but subsided by days 7 and 14. Loss of myenteric
neurons was seen on days 7 and 14, accompanied by
Table 1 Speed of transit and emptying following repeated in vivo
5-fluorouracil administration
Parameters
measured Day 0 Day 3 Day 7 Day 14
Speed of transit (time to reach each region, min)
Stomach 0  0 0  0 0  0 0  0
Small
intestines
5  0 5  0 5  0 5  0
Cecum 70  3 53  3*** 80  5* 83  4**
Large
intestines
90  3 66  3**** 105  4*** 113  4****
Time for complete barium emptying (min)
Gastric
emptying
17  1 16  1 63  6* 63  3**
Intestinal
emptying
88  2 63  3** 105  4* 126  8*
Pellet
formation
90  3 66  3**** 105  4*** 113  4****
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, significantly dif-
ferent to Day 0 (n = 5 per/group).
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reduced numbers of ChAT-IR neurons at these time
points.
Although 5-F U is routinely used in the treatment of
CRCand is known to cause gastrointestinal side-effects,
the neurological mechanisms underlying these side-
effects have not been studied.31,32 Our study demon-
strates that, while short-term 5-FU treatment acceler-
ates overall gastrointestinal transit without a change in
gastric emptying, more prolonged treatment results in
significant delays to overall gastrointestinal transit,
gastric emptying and intestinal emptying. Our findings
are consistentwith previous studies showing that short-
and long-term administration of the chemotherapeutic
agent cisplatin differentially alters gastrointestinal
transit.19,20 Our findings suggest that mechanisms
underlying these differential changes in transit are
different. Accelerated gastrointestinal transit observed
after 3 days of treatment was associated with acute
intestinal inflammation and reduced proportions of
nNOS-IR neurons. Intestinal inflammation was
resolved after days 7 and 14 when delays to overall
gastrointestinal transit, gastric, and intestinal empty-
ing, and colonic dysmotility were observed. The loss of
myenteric neurons observed at these time points might
contribute to the functional changes in the gastroin-
testinal tract. Gastric and intestinal transit has previ-
ously been investigated using radioactivity retention
technique in ratswhere itwas found that delayed gastric
empting and increased fundus and duodenum muscle
contractions occurred 3 and 15 days after a single high
dose of 5-FU (150 mg/kg) injection.13 However, our
study is the first to use radiographic analysis to evaluate
overall gastrointestinal transit alongside ENS damage
following 5-FU administration in mice. Postinflamma-
tory delays to gastric and intestinal emptying have been
reported in a plethora of gastrointestinal disorders.33–35
Gastric emptying of solids is significantly delayed in
patients with postinfectious functional dyspepsia, irri-
table bowel syndrome, non-obstructive Crohn’s disease
and colitis.34–38
A B C
A′ B′ C′
Figure 4 Gross morphological changes in
the colon following repeated in vivo 5-FU
administration. H&E staining in the colon
from sham and 5-FU -treated mice at 3 (A,
A’), 7 (B, B’), and 14 (C, C’) days. Scale
bar = 100 lm, n = 4 per group/time point.
Figure 3 Total number, proportion, and speed of different contractions following repeated in vivo 5-FU administration. (A) Representative
spatiotemporal maps generated from digital video recordings of colonic motility from sham and 5-FU-treated mice. Each contraction can be seen as a
reduction in the gut width (red), while relaxation as an increase in the gut width (blue). Colonic migrating motor complexes (CMMCs) propagate
>50% of the colon length, short contractions (SCs) propagate <50% of the colon length and fragmented contractions (FCs) are interrupted by period(s)
of relaxation during contraction. (B) Total number of contractions including all types of contractile activity in the colons from sham and 5-FU-treated
mice. (C) The proportion of CMMCs, SCs, and FCs to the total number of contractions. (D) The speed of CMMCs, SCs, and FCs. Data represented as
mean  SEM. **p < 0.01, ****p < 0.0001, n = 6 per group/time point. (E) Spatiotemporal maps from day 14 sham and 5-FU-treated mice after
addition of tetrodotoxin (TTX, 1 lM, 20 min) and hexamethonium (HEX, 100 lM, 20 min).
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Mucosal inflammation, epithelial degradation and
intestinal ulceration, manifesting as mucositis, follow-
ing 5-FU administration have been suggested as causes
of gastrointestinal dysfunction.12Our results show that,
while short-term 5-FU treatment was associated with
destruction of the epithelial brush border and severe loss
of colonic crypts and goblet cells, chronic treatment did
not worsen epithelial damage. In fact regeneration of
mucosa was evident during chronic 5-FU treatment,
although crypts still appeared shorter, distended, and
disorganized. These results are consistentwith previous
findings in the rat duodenum following 3 days of 5-FU
treatment, where loss of crypt architecture, shortening
of villi and inflammatory infiltration in the lamina
propria was reported.13 This was followed by the
restoration of intestinal villi and crypts following
15 days of 5-FU treatment, but with sparse neutrophil
infiltration in the muscular layer.13 Such evidence
indicates that duodenal mucosal inflammation resolves
during 15 days of 5-FU treatment.
Both in vitro and in vivo treatment with 5-FU
promote the attraction of inflammatory cells.39 Intesti-
nal inflammation is associated with gastrointestinal
dysmotility both at the site of inflammation and at
distant non-inflamed sites.40–42 Further to this a
A B C
A′ B′ C′
D E
Figure 5 Inflammatory markers in the
colon and fecal pellets. Cross-sections of the
colon labeled with antibody against CD45+
leukocytes (green) following 3 (A, A’), 7 (B,
B’), and 14 (C, C’) days of sham or 5-FU
treatment, scale bar = 50 lm. Average
number of CD45+ cells in the colon was
counted per 2 mm2 at 3, 7 and 14 days in
both sham and 5-FU treated mice. (D)
Concentration of lipocalin-2 (ng/mL) in fecal
pellets collected following 3, 7, and 14 days
of 5-FU administration (E). Data represented
as mean  SEM. *p < 0.05, ****p < 0.0001,
n = 4 per group/time point.
Figure 6 Effect of repeated in vivo 5-FU administration on the total
number of myenteric neurons. Average number of PGP9.5-IR neurons
in the colon was counted per 2 mm2 at 3, 7, and 14 days in both sham
and 5-FU-treated mice. Data represented as mean  SEM.
***p < 0.001, n = 6 per group/time point.
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number of inflammatory mediators have been impli-
cated in both short- and long-term smooth muscle
contractility changes.43 Accordingly, many gastroin-
testinal side-effects experienced during and after 5-FU
administration have been attributed to inflammation-
induced mucosal damage which we observed in the rat
model of acute toxicity induced by a high dose (150 or
300 mg/kg) of 5-FU (R. Abalo, unpublished data) and in
this study after a short-term treatment of mice with a
low dose (23 mg/kg) of 5-FU. However, 5-FU-induced
gastrointestinal dysmotility appears to outlast intesti-
nal mucositis,13 indicating that a more complex and
multifaceted pathophysiology is at play.
Our results show that chronic 5-FU administration
results in significant neuronal loss in the myenteric
plexus of the colon at days 7 and 14 when intestinal
A A′
B B′
C C′
D E
Figure 7 Effect of repeated in vivo 5-FU
administration on average number and
proportion of nNOS-IR myenteric neurons.
Wholemount preparations of myenteric
neurons in colon following 3 (A, A’), 7 (B, B’),
and 14 (C, C’) days of sham or 5-FU
treatment, scale bar = 50 lm. (D) Average
number of nNOS-IR neurons (green in A–C)
in the colon was counted per 2 mm2 at 3, 7
and 14 days in both sham and 5-FU treated
mice. (E) Proportion of nNOS-IR neurons
(green in A–C) to the total number of
PGP9.5-IR myenteric neurons (magenta in
A–C) in the colon was counted at 3, 7, and
14 days in both sham and 5-FU-treated
mice. Gray column: sham-treated, black
column: 5-FU-treated. Data represented as
mean  SEM. **p < 0.01, ****p < 0.0001,
n = 6 per group/time point.
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inflammation subsided. Our findings are consistentwith
previous studies investigating effects of platinum-based
anticancer chemotherapeutics,which also demonstrated
that long-term treatments induce loss of myenteric
neurons.15,16 However, 5-FU treatment induced less
severe damage to myenteric neurons with 12% loss at
day14compared to25%ofmyentericneuronal lossatday
14 of oxaliplatin treatment.15 Although previous studies
demonstrated that the loss of enteric neurons does not
necessarily lead to changes in CMMCs44,45 our results
demonstrated that the loss of myenteric neurons corre-
latedwith colonic dysmotility in 5-FU-treatedmice. The
loss of myenteric neurons leads to long-term alterations
in gastrointestinal functions as was shown in rats after
cisplatin treatment16 and mice after oxaliplatin treat-
ment.15 5-FU treatment inhibited CMMCs, but the total
number of contractions of the isolated colon was signif-
icantly increased due to an increase in the number and
A A′
B B′
C C′
D E
Figure 8 Effect of repeated in vivo 5-FU
administration on the average number and
proportion of ChAT-IR myenteric neurons.
Wholemount preparations of myenteric
neurons in the colon following 3 (A, A’), 7 (B,
B’), and 14 (C, C’) days of sham or 5-FU, scale
bar = 50 lm. (D) Average number of ChAT-
IR neurons (green in A–C) in the colon was
counted per 2 mm2 at 3, 7, and 14 days in
both sham and 5-FU-treated mice. (E)
Proportion of ChAT-IR neurons (green in A–
C) was counted to the total number of
PGP9.5-IR myenteric neurons (magenta in
A–C) in the colon was counted per 2 mm2 at
3, 7, and 14 days in both sham and 5-FU
treated mice. Gray column: sham-treated,
black column: 5-FU-treated. Data
represented as mean  SEM. **p < 0.01,
****p < 0.0001, n = 6 per group/time point.
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proportionofshort andFCs.Short andFCsplayavital role
in the construction of productive motor patterns in the
healthy intestine.25 Short distance contractions result
in a segmenting motor pattern essential for mixing
and absorption of colonic contents.46 Alteration in
short segmenting contractions induces intestinal
dysmotility.47
Our results demonstrated that all types of contrac-
tions were neurogenic; residual tonic constriction in
the distal colon was blocked by HEX in both sham and
5-FU-treated mice. Tetrodotoxin-resistant tonic con-
striction in the proximal colon observed in 5-FU–
treated mice was not blocked by HEX. These results
suggest that there is TTX-insensitive tonic excitatory
drive to the smooth muscle that presumably involves
at least one nicotinic synapse and hence must involve
neurons with TTX-resistant action potentials like
those described by Foong et al. in the mouse submu-
cosal plexus.48 This activity seems to be differentially
sensitive to 5-FU. Thus, initial acute inflammation
caused by 5-FU treatment may have led to persistent
changes in the ENS and gut dysfunction. Similarly, in
animal models of intestinal inflammation, long-term
gut dysfunction persists long after resolution of acute
inflammation due to neuronal loss, axonal damage, and
neuronal dysfunction in the myenteric plexus leading
to changes in synaptic transmission between neurons
and to the smooth muscles.26,49–54
We found that long-term treatment with 5-FU
induced loss of both excitatory (ChAT-IR) and inhibi-
tory (nNOS-IR) neurons in the myenteric plexus.
However, only nNOS-IR neuron proportions were
reduced at day 3 post 5-FU treatment, which is
consistent with increased intestinal transit at this
time point. Loss of nNOS-IR neurons was also
observed in cisplatin and oxaliplatin-treated ani-
mals15,16 however, ChAT-IR neurons were not inves-
tigated in these studies. Thus, our results suggest that
the loss of neurons after 5-FU treatment is not
restricted to a specific neurochemically defined sub-
population. Differential effects of various chemother-
apeutic compounds on enteric neurons might be
attributed to the differences in their mechanisms of
action with platinum-based compounds having direct
neurotoxicity due to platinum adducts to DNA55
compared to inflammation-induced neuropathy asso-
ciated with 5-FU treatment.13
Damage to the intestinal smooth muscles, alter-
ations in neuromuscular transmission, smooth muscle
sensitivity to neurotransmitters and morphological
and functional changes of interstitial cells of Cajal
might be also involved in 5-FU-induced dysmotility
and these require further investigation.
In conclusion, this study is the first to demonstrate
that 5-FU administration induces accelerated gastroin-
testinal transit associated with acute intestinal inflam-
mation at day 3 post-treatment, which may have led to
persistent changes in the ENS and gastrointestinal
dysfunctions: delayed gastrointestinal transit, gastric
and intestinal emptying, and colonic dysmotility. The
loss of myenteric neurons observed at days 7 and 14 of
treatment may contribute to the functional changes in
the gastrointestinal tract. Further research investigat-
ing the effects of 5-FU on the electrophysiological
properties of myenteric neurons is warranted.
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